Abstract
Changes in the levels of free fatty acids (FFAs) are closely associated with physiological status. Serum levels of C16:1, C18:3, C18:2, C18:1, C20:4, and C22:6 in 164 gastric cancer (GC) patients and 111 benign gastric disease (BGD) patients were significantly decreased compared with 252 healthy controls. Receiver operating characteristic analysis showed that the biomarker panel including C16:1, C18:3, C18:2, C20:4, and C22:6 presents a high diagnostic ability to differentiate early-stage GC patients from healthy controls plus BGD patients, with a sensitivity of 80.6% and a specificity of 72.7%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
